Loading organizations...
§ Private Profile · Cambridge, MA, USA
Synlogic is a technology company.
Synlogic develops synthetic biotic medicines, leveraging advanced synthetic biology to engineer living therapeutics. These novel, oral, non-systemically absorbed biotherapeutics deliver targeted activities locally. The company's approach reprograms microbes to address underlying causes of serious diseases, offering a differentiated treatment modality.
Founded in 2014 by synthetic biology experts James Collins, PhD, and Timothy Lu, MD, PhD, Synlogic emerged from the Massachusetts Institute of Technology. Their insight centered on genetically engineering commensal bacteria into precision therapeutic agents. These renowned founders established the company to apply synthetic biology to medicine.
Synlogic's therapies target patients afflicted with serious metabolic disorders, rare diseases, and other complex conditions. The company envisions transforming patient care by harnessing the microbiome to create new living medicines. Its long-term mission is to establish synthetic biotics as a cornerstone therapeutic, providing innovative solutions for unmet medical needs.
Synlogic has raised $116.0M across 4 funding rounds.
Synlogic has raised $116.0M in total across 4 funding rounds.
Synlogic has raised $116.0M across 4 funding rounds. Most recently, it raised $42.0M Series C in May 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2017 | $42M Series C | — | Atlas Venture, MPM Capital, Hakan Goker, Nest.bio Labs, ED Mathers, NEW Enterprise Associates, RA Capital, Santé Ventures | Announced |
| Feb 1, 2016 | $40M Series B | Chau Khuong | Atlas Venture, MPM Capital, Hakan Goker, RA Capital, Deerfield Management, NEW Enterprise Associates | Announced |
| Oct 1, 2014 | $5M Series A | Trevor Mundel | Atlas Venture, MPM Capital, Hakan Goker, RA Capital | Announced |
| Jul 1, 2014 | $29M Series A | Atlas Venture, NEW Enterprise Associates | MPM Capital, Hakan Goker, RA Capital, Santé Ventures | Announced |
Synlogic has raised $116.0M in total across 4 funding rounds.
Synlogic's investors include Atlas Venture, MPM Capital, Hakan Goker, Nest.Bio Labs, Ed Mathers, New Enterprise Associates, RA Capital, Santé Ventures, Chau Khuong, Deerfield Management, Trevor Mundel.
Synlogic is a clinical-stage biopharmaceutical company pioneering Synthetic Biotics, living therapeutics engineered from probiotics using synthetic biology to treat serious metabolic disorders.[1][2][4] It develops oral, GI-restricted medicines that target underlying biology, with a lead program in phenylketonuria (PKU) via labafenogene marselecobac (SYNB1934) in a pivotal Phase 3 study (Synpheny-3), alongside candidates for homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria.[3] Synlogic serves patients with rare metabolic diseases underserved by current treatments, solving problems like toxic metabolite accumulation through precision genetic engineering that consumes or produces specific biological targets in the gut.[1][3] The company, headquartered in Cambridge, Massachusetts, trades as SYBX on Nasdaq with a lean team of under 25 employees and revenue below $5 million, focusing on data-driven advancement of its proprietary pipeline.[1][3]
Synlogic emerged from breakthroughs in synthetic biology, leveraging a reproducible, modular approach to microbial engineering for medicine.[1] Founded before its 2015 IPO (September 30), the company has evolved from early research collaborations—like with Roche on inflammatory bowel disease and Ginkgo Bioworks on preclinical assets—to clinical proof-of-concept, including plans for a PKU Phase 3 study announced around 2022.[2][3] Key milestones include 2023 financial reporting and pipeline expansion into immunology and additional metabolic indications, humanizing its mission at the "point of convergence" between human compassion and scientific logic.[2][4] While specific founders are not detailed in available data, the team's focus on nurturing talent has driven rapid progression from discovery to pivotal trials.[2]
Synlogic stands out in biotech through these key strengths:
Synlogic rides the synthetic biology wave, merging engineering with biology to redefine therapeutics amid rising demand for precision medicines in rare diseases.[4] Timing aligns with advances in microbial engineering and probiotics, fueled by market forces like unmet needs in metabolic disorders (e.g., PKU affects ~1 in 10,000-15,000 births) and regulatory interest in living drugs.[1][3] It influences the ecosystem by validating Synthetic Biotics as a new paradigm—potentially transformative for GI-restricted treatments—while collaborations amplify innovation, positioning it as a leader in biologics beyond traditional small molecules or gene therapies.[2][4]
Synlogic's path forward hinges on Phase 3 success in PKU, with topline data potentially catalyzing partnerships, approvals, or acquisitions in the burgeoning synbio therapeutics market.[3] Trends like AI-driven protein design and expanded microbiome research will accelerate its pipeline, evolving its influence from niche metabolic pioneer to broader immunology player.[2] As biotech rebounds, Synlogic's lean, platform-driven model could deliver first-in-class oral biotics, bringing the transformative potential of synthetic biology to patients long underserved by conventional care.[1][4]